Table 2.
Case | Age | Sex | WHO grade | Mitoses/hpf | Location | Outcome |
---|---|---|---|---|---|---|
1 | 74 | Male | III | 4/10 | Right frontal | DOD 2.5 years later |
2 | 51 | Female | “Atypical features” | 0/10 | Left parietal | Recurrence 4 years later with malignant transformation to GBM; DOD 1 year after recurrence |
3 | 45 | Male | “Atypical features” | 1/10 | Right temporal | Recurrence 6 years later diagnosed as grade II‐III astrocytoma, treated with temozolomide and radiation |
4 | 45 | Male | “Atypical features” | 0/10 | Left frontal | Postsurgical radiation, recurrence 5 years later, progression to grade III oligodendroglioma two years after initial recurrence; DOD 13 years after original diagnosis |
5 | 52 | Male | I | 0/10 | Frontal | Radiation after surgery, recurrence 15 years after initial diagnosis; no follow‐up information since then |
6 | 20 | Male | I | 2/10 | Left posterior frontal lobe | Recurrence 5 years after diagnosis, treated with radiation |
7 | 44 | Male | I | 2/10 | Not specified | Alive 8 years after surgery, no additional information available |
8 | 38 | Female | “Atypical features” | 0/10 | Right parietal | Residual/recurrent tumor within 1 year of surgery, treated with radiation |
Eight of the 98 cases studied had IDH1 mutations; all were wild type for IDH2. Common features include advanced age and trends toward extratemporal location and mitoses. Most have already shown aggressive behavior.